Translate Bio Inc. (NASDAQ:TBIO) shares traded higher over the last trading session, gaining 16.32% on 12/11/20. The shares fell to a low of $21.83 before closing at $25.09. Intraday shares traded counted 3.65 million, which was -247.85% lower than its 30-day average trading volume of 1.05M. TBIO’s previous close was $21.57 while the outstanding shares total 73.18M. The stock’s Relative Strength Index (RSI) is 76.41, with weekly volatility at 8.78% and ATR at 1.46. The TBIO stock’s 52-week price range has touched low of $6.80 and a $28.09 high.
Investors have identified the Biotechnology company Translate Bio Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $1.60 billion, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Translate Bio Inc. (TBIO) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. In terms of their assets, the company currently has 710.96 million total, with 124.02 million as their total liabilities.
TBIO were able to record 252.86 million as free cash flow during the Q3 2020 quarter of the year, this saw their quarterly net cash flow reduce by 589.47 million. In cash movements, the company had a total of 258.29 million as operating cash flow.
Potential earnings growth for Translate Bio Inc. (TBIO)
In order to determine the future investment potential for this stock, we will have to analyze key trends that affect it. During the Q3 2020 quarter of the year, Translate Bio Inc. recorded a total of 66.45 million in revenue. This figure implies that they witnessed a quarterly year/year change in their earnings with 98.09% coming in sequential stages and their sales for the Q3 2020 quarter increasing by 75.44%.
What matters though is how it ends. When the core data for the company is broken down, then the stock sounds interesting. The company spent 66.45 million trying to sell their products during the last quarter, with the result yielding a gross income of 49.7 million. This allows shareholders to hold on to 73.18M with the recently reported earning now reading 0.24 cents per share. This is a figure that compared to analyst’s prediction for their Q3 2020 (0.23 cents a share).
Having a look at the company’s valuation, the company is expected to record -1.02 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on TBIO sounds very interesting.
Is the stock of TBIO attractive?
In related news, Director, FORMELA JEAN FRANCOIS sold 10,097 shares of the company’s stock in a transaction that recorded on Aug 27. The sale was performed at an average price of 14.38, for a total value of 145,217. As the sale deal closes, the Director, FORMELA JEAN FRANCOIS now sold 44,381 shares of the company’s stock, valued at 656,746. Also, Director, FORMELA JEAN FRANCOIS sold 34,410 shares of the company’s stock in a deal that was recorded on Aug 25. The shares were price at an average price of 15.00 per share, with a total market value of 516,160. Following this completion of acquisition, the 10% Owner, Shire Human Genetic Therapies, now holds 6,824,992 shares of the company’s stock, valued at 141,140,835. In the last 6 months, insiders have changed their ownership in shares of company stock by 0.70%.
9 out of 9 analysts covering the stock have rated it a Buy, while 0 have maintained a Hold recommendation on Translate Bio Inc.. 0 analysts has assigned a Sell rating on the TBIO stock. The 12-month mean consensus price target for the company’s shares has been set at $31.00.